SCHEMBL6350686

SCHEMBL6350686

CC(=O)N(CC(=O)c1ccccc1)C(C(=O)O)c1ccccc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.46
ALDH1A1 P00352 4/20 0.46
USP2 O75604 1/20 0.46
KMT2A Q03164 5/20 0.45
TSHR P16473 1/20 0.43
MEN1 O00255 4/20 0.41
MAPT P10636 3/20 0.41
MAPK1 P28482 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
CYP3A4 P08684 1/20 0.41
HPGD P15428 1/20 0.41
ALOX15 P16050 1/20 0.41
CES1 P23141 1/20 0.41
TDP1 Q9NUW8 1/20 0.41
ATM Q13315 1/20 0.41
AGTR1 P30556 1/20 0.41
TRPM8 Q7Z2W7 2/20 0.40
ROCK2 O75116 1/20 0.40
EGFR P00533 1/20 0.39
GSK3B P49841 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6358138 0.88 TRPM8 (0.51) KDM4EALDH1A1USP2KMT2AMEN1
SCHEMBL27855089 0.80 NR1H2 (0.47) ALDH1A1TSHRMAPTMAPK1SMN1; SMN2
SCHEMBL628344 0.80 NR1H2 (0.47) ALDH1A1TSHRMAPTMAPK1SMN1; SMN2
SCHEMBL6345185 0.79 KDM4E (0.45) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL6350978 0.79 ALDH1A1 (0.45) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL6349361 0.79 ALDH1A1 (0.45) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL6356051 0.79 ALDH1A1 (0.45) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL2333269 0.78 ALDH1A1 (0.44) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL6350983 0.77 ALDH1A1 (0.43) KDM4EALDH1A1USP2KMT2ATSHR
SCHEMBL6360094 0.76 KDM4E (0.42) KDM4EALDH1A1USP2KMT2ATSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6960575-B2 For use as inhibitors of chymase SANTEN PHARMACEUTICAL CO., LTD. (JP) 2005-11-01 US disclosed
US-20040097496-A1 Novel thiazine derivatives SANTEN PHARMACEUTICAL CO.,LTD. (JP) 2004-05-20 US disclosed
US-6713472-B1 2-OXO-1,2,3,4-TETRAHYDROPYRAZINE DERIVATIVES; CHYMASE INHIBITORS SANTEN PHARMACEUTICAL CO., LTD. (JP) 2004-03-30 US disclosed
EP-1211249-A1 NOVEL THIAZINE OR PYRAZINE DERIVATIVES SANTEN PHARMACEUTICAL CO., LTD. (JP) 2002-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040097496-A1 Novel thiazine derivatives CMA1, TPSD1, HRH4 KDM4E 2934/4885ALDH1A1 420/4885USP2 1460/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.